Aileron Therapeutics (NASDAQ:ALRN) enrolled the first patients in its Phase 1b clinical trial evaluating ALRN-6924 for bone marrow in patients patients with p53-mutated breast cancer who are being treated with doxorubicin plus cyclophosphamide and docetaxel (AC+D).
Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, said, “The severe toxicity profile of AC+D will enable us to evaluate ALRN-6924's protective effect against multiple chemotherapy-induced toxicities. Moreover, this breast cancer trial may potentially open an additional regulatory opportunity with established precedents for supportive care drug approvals.”
The company has previously presented non-clinical proof of mechanism data demonstrating ALRN-6924, also proof of mechanism data for cell cycle arrest in bone marrow stem cells and hair follicle cells in healthy human volunteers.
Around one million patients are diagnosed with a p53-mutated cancer every year in the United States.
Aileron Therapeutics closed Wednesday’s trading up 3 percent at $0.44
